From: Current perspectives on cardiovascular outcome trials in diabetes
Concomitant medication @baseline | Antihyperglycemic medication N (%) | CV treatment N (%) | |||||||
---|---|---|---|---|---|---|---|---|---|
Insulin | Metformin | Sulphonylurea | Aspirin | Statins | Antiplatelet/anticoagulant | Beta-blocker | ACEI/ARB | Other anti-hypertensives | |
SAVOR-TIMI53 | 6757 (40.9) | 11,094 (67.4) | 6332 (38.5) | 12,390 (75.2) | 12,892 (78.3) | 13,386 (81.3) | 10,117 (61.4) | 12,935 (78.5) | 6730 (40.9) |
EXAMINE | 1605 (29.8) | 3562 (66.2) | 2503 (69.9) | 4881 (90.7) | 4866 (90.4) | 5232 (97.2) | 4411 (81.9) | 4411 (81.9) | 1197 (22.2) |
TECOS | 3408 (23.2) | 11,966 (81.6) | 6645 (45.3) | 11,518 (78.5) | 11,719 (79.9) | 3167 (21.7) | 9322 (63.5) | 11,555 (78.8) | 4961 (33.8) |
ELIXA | 2292 (37.8) | 3834 (63.2) | 1863 (30.7) | 5726 (94.4) | 5621 (92.6) | 480 (7.9) | 5119 (84.4) | 5151 (84.9) | 1327 (21.9) |
EMPA-REG OUTCOME | 2394 (34)a | 3933 (55.9)a | 1383 (19.6) | 5990 (85) | 5387 (77) | – | 4537 (64) | 5651 (80) | 2114 (30) |
LEADER | 3905 (41.8)a | 7136 (76.4) | 4721 (50) | 6523 (69.8) | 6729 (72) | 6322 (67.7) | 5173 (55.4) | 4761 (51) | 920 (9.85) |
SUSTAIN-6 | 1913 (58.0) | 2414 (73.2) | 1410 (42.8) | 2108 (63.9) | 2399 (72.8) | 406 (12.3) | 1894 (57.4) | 1642 (49.8) | 258 (7.8) |
CAROLINA | – | 4982 (82.5) | 1728 (28.6) | 3026 (50.1) | 3872 (64.1) | – | 2344 (38.8) | 2664 (44.1) | 1770 (29.3) |
CANVAS | 2171 (50.1) | 3158 (72.9) | 2032 (46.9) | Â | 3119 (72.0) | 3073 (71.0) | Â | Â | Â |